Neuraxis, Inc. (NRXS) is a publicly traded Healthcare sector company. As of May 21, 2026, NRXS trades at $7.26 with a market cap of $91.77M and a P/E ratio of -7.64. NRXS moved -0.69% today. Year to date, NRXS is +64.40%; over the trailing twelve months it is +81.70%. Its 52-week range spans $1.33 to $9.33. Analyst consensus is buy with an average price target of $0.00. Rallies surfaces NRXS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Neuraxis Q1 Revenue Climbs While Reimbursement Hurdles Delay Cash Conversion: Neuraxis delivered robust first-quarter revenue growth while encountering delays in insurance coverage approvals for its neurosurgical monitoring services. Management warned these reimbursement issues are extending days-sales-outstanding and could pressure operating cash flows in the coming quarters.
| Metric | Value |
|---|---|
| Price | $7.26 |
| Market Cap | $91.77M |
| P/E Ratio | -7.64 |
| EPS | $-0.95 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.33 |
| 52-Week Low | $1.33 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $3.57M |
| Net Income | $-7.80M |
| Gross Margin | 84.23% |
1 analysts cover NRXS: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $0.00.